Background/Aim: Meta-analyses are frequently performed on adverse event data and are primarily used for improving statistical power to detect safety signals. However, in the evaluation of drug safety for New Drug Applications, simple pooling of adverse event data from multiple clinical trials is still commonly used. We sought to propose a new Bayesian hierarchical meta-analytic approach based on consideration of a hierarchical structure of reported individual adverse event data from multiple randomized clinical trials. Methods: To develop our meta-analysis model, we extended an existing three-stage Bayesian hierarchical model by including an additional stage of the clinical trial level in the hierarchical model; this generated a four-stage Bayesian hierarchical model. We applied the proposed Bayesian meta-analysis models to published adverse event data from three premarketing randomized clinical trials of tadalafil and to a simulation study motivated by the case example to evaluate the characteristics of three alternative models. Results: Comparison of the results from the Bayesian meta-analysis model with those from Fisher's exact test after simple pooling showed that 6 out of 10 adverse events were the same within a top 10 ranking of individual adverse events with regard to association with treatment. However, more individual adverse events were detected in the Bayesian meta-analysis model than in Fisher's exact test under the body system ''Musculoskeletal and connective tissue disorders.'' Moreover, comparison of the overall trend of estimates between the Bayesian model and the standard approach (odds ratios after simple pooling methods) revealed that the posterior median odds ratios for the Bayesian model for most adverse events shrank toward values for no association. Based on the simulation results, the Bayesian meta-analysis model could balance the false detection rate and power to a better extent than Fisher's exact test. For example, when the threshold value of the posterior probability for signal detection was set to 0.8, the false detection rate was 41% and power was 88% in the Bayesian meta-analysis model, whereas the false detection rate was 56% and power was 86% in Fisher's exact test. Limitations: Adverse events under the same body system were not necessarily positively related when we used ''system organ class'' and ''preferred term'' in the Medical Dictionary for Regulatory Activities as a hierarchical structure of adverse events. For the Bayesian meta-analysis models to be effective, the validity of the hierarchical structure of adverse events and the grouping of adverse events are critical. Conclusion: Our proposed meta-analysis models considered trial effects to avoid confounding by trial and borrowed strength from both within and across body systems to obtain reasonable and stable estimates of an effect measure by considering a hierarchical structure of adverse events.
statistical power: most clinical trials are designed to confirm primary efficacy endpoints, and the trials typically have insufficient power to detect betweentreatment differences in safety endpoints, particularly for rare AEs. Second, multiplicity: the number of individual AEs, for example, can be extremely large, occasionally on the order of hundreds or even thousands in late-stage clinical trials; thus, an appropriate approach must be used that can effectively balance false-positive and false-negative rates. Third, medical classification: medically related AEs are grouped into categories, and these AEs in clinical trials are typically coded in terms using a common dictionary (e.g. Medical Dictionary for Regulatory Activities) with a specific hierarchical structure such as a body system (system organ class in Medical Dictionary for Regulatory Activities) composed by individual AE terms (preferred term in Medical Dictionary for Regulatory Activities). The efficient use of such information is a statistical challenge. Here, we propose a Bayesian meta-analytic approach to overcome these three statistical challenges.
Bayesian approaches are useful for detecting safety signals, 3, 7 and certain Bayesian methods have been proposed for analyzing the postmarketing spontaneous reports database. 8, 9 From a regulatory perspective, Chi et al. 10 noted the following: ''Safety assessment is one area where frequentist strategies have been less applicable. Perhaps Bayesian approaches in this area have more promise.'' For analyzing AE data in clinical trials, Berry and Berry 11 proposed a Bayesian hierarchical model; they treated AE data as binary outcomes and modeled coded AE data with a hierarchical structure under the condition that AEs under the same body system are more similar and medically related than those under distinct body systems. Xia et al. 12 extended the Bayesian hierarchical model to a Poisson model to account for differences in treatment durations between treatment groups. Using this model, we can explicitly and concurrently model individual AEs with coding structures such as system organ class and preferred term that are typically tabulated in clinical trial reports. The model also offers these other advantages: first, it suitably provides estimates that are partially corrected for multiplicity when most of the AEs are expected to be unassociated with treatment; this means that the model controls the detection of false positives and concomitantly adjusts multiplicity depending on the similarity of AEs within a hierarchical structure. Second, it efficiently analyzes the entire AE dataset and modulates the extremes. These features are particularly desirable for rare AEs.
Meta-analyses are frequently performed on AE data [13] [14] [15] and are primarily used as methods for improving statistical power to detect safety signals of rare AEs. 16, 17 When performing meta-analyses of randomized clinical trials, the data analysis must preserve the structure of the trial design using valid statistical methods that stratify by trial to preserve the randomization scheme. 18, 19 However, simple pooling of AE data from multiple clinical trials is still commonly adopted when evaluating drug safety for New Drug Applications. One reason for this is that the International Conference on Harmonization introduces simple pooling methods when data are presented in an Integrated Summary of Safety. 20 However, analysis results obtained from simple pooling methods can lead to inaccurate interpretations. [21] [22] [23] [24] Furthermore, the potential for confounding by trial is strengthened because the imbalance in the distribution of participants' characteristics is occasionally not evaluable from aggregate trial data. Therefore, it is necessary to use a valid meta-analytic approach featuring appropriate adjustments and weights for distinct trials.
In this study, we aimed to develop a new Bayesian hierarchical meta-analytic approach by extending a Bayesian hierarchical model proposed by Berry and Berry 11 and Xia et al. 12 based on consideration of a hierarchical structure of reported individual AE data from multiple randomized clinical trials. We compared three alternative models using published AE data from three premarketing randomized clinical trials of tadalafil and through a small simulation study based on a case example. We focused on comparing the results obtained from simple pooling methods and the three models rather than model selection to assess the characteristics of the models and provide suggestions for practical use of the Bayesian meta-analysis models.
Case example
As a sample case, we analyzed a series of placebocontrolled trials for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Nishizawa et al. 25 assessed the efficacy and safety of tadalafil (5 mg, administered once-daily) by pooling the data of 1199 patients administered placebo (n = 598) or tadalafil 5 mg (n = 601) from three premarketing randomized, double-blind, placebo-controlled, 12-week trials (a phase II trial in Japan (LVIA Study: placebo (n = 140) and tadalafil (n = 140)) and two phase III trials in Asia (LVHB Study: placebo (n = 154) and tadalafil (n = 155) and LVJF Study: placebo (n = 304) and tadalafil (n = 306))). These trials were similar with regard to design, participation criteria, and efficacy/safety endpoints.
Overall, tadalafil for up to 12 weeks of treatment was safe and well-tolerated in this pooled population. Because all of the individual AEs were not reported in the article, we extracted the AEs from the regulatory submission documents for the New Drug Application (available at: http://www.pmda.go.jp/ drugs/2013/P201300159/index.html in Japanese); these are tabulated in the web appendix Table 1 . We found that 193 individual AEs (preferred terms) were present within 22 body systems (system organ classes), which included 1-34 individual AEs. For example, 19 individual AEs such as myalgia and back pain were included under the body system ''Musculoskeletal and connective tissue disorders,'' which constituted the hierarchical structure of the AEs. In the following analyses, we focused on the placebo and tadalafil 5 mg once-daily groups as Nishizawa et al. did.
Methods

Bayesian meta-analysis models
To develop our meta-analysis model, we extended a three-stage Bayesian hierarchical model proposed by Berry and Berry 11 and Xia et al. 12 by including an additional stage of the clinical trial level in the hierarchical model; this resulted in the proposed four-stage Bayesian hierarchical model for AE data from multiple clinical trials. Here, we describe three Bayesian models: the first two are newly proposed four-stage Bayesian meta-analysis models, and the third is a nonhierarchical model for the structure of AE data and was used for comparison with the first two models.
Model 1: Bayesian meta-analysis model with normal prior on log-odds ratio. We extended a Bayesian hierarchical model (Model 1a in the article by Xia et al. 12 ) to Model 1 as follows. X ijk and Y ijk were taken as the number of patients presenting an AE in the jth preferred term, for j = 1, ., p i , under the ith system organ class, for i = 1, ., I, in the kth clinical trial, for k = 1, ., K, for placebo and treatment groups, respectively. N ck and N tk were taken as the number of patients in the kth clinical trial for placebo and treatment groups, respectively.
We assumed a binomial likelihood for the number of patients presenting an AE, that is, X ijk ; Binom(N ck , z ijk ) and Y ijk ; Binom(N tk , h ijk ), where z ijk and h ijk are the probabilities of incidence of an AE for the jth preferred term under the ith system organ class in the kth clinical trial for placebo and treatment groups, respectively. As a mean structure, we considered a logistic regression:
Listed below are the Stage-1 prior distributions; g ijk and u ijk exhibited a normal prior distribution
Stage 1 corresponds to the clinical trial level, and we conducted a meta-analysis for individual AEs at this stage. Following Stage 1, we set the prior distributions to the hyperparameters through Stages 2-4 with the same principle used in the original Bayesian hierarchical model. 11, 12 Specifically, normal distributions and inverse gamma (IG) distributions were set to the means and the variances, respectively. The prior distributions of these stages were the following:
Stage 3, body system (system organ class) level
a ui , and b ui were considered fixed constants. In our analysis, we used the same values used by Berry and Berry 11 and Xia et al. 12 : m g00 = m u00 = 0, t 2 g00 = t 2 u00 = 10, a g00 = a u00 = a g = a u = a gi = a ui = 3,
Model 2: Bayesian meta-analysis model with mixture prior on log-odds ratio. We extended Bayesian hierarchical models (the model proposed by Berry and Berry 11 and Model 1b by Xia et al. 12 ) to Model 2 as follows. We assumed the same likelihood and mean structure as in Model 1, but changed the prior distribution for the mean of the log-odds ratios to a mixture distribution
is a distribution featuring a unit point mass at 0. Positive probability was assigned to the possibility of equality between the placebo and treatment proportions. We used the same prior distributions for the common parameters as in Model 1. For the hyperparameters not included in Model 1, these were the prior distributions
The left-truncated exponential prior distributions for a p and b p were chosen. Restricting the parameters to .1 prevents the posterior density of p i from becoming exceedingly concentrated at 0 and 1.
We used the same fixed values for the hyperparameters m g00 , t 2 g00 , m u00 , t 2 u00 , a g00 , b g00 , a u00 , b u00 , a g , b g , a u , b u , a gi , b gi , a ui , and b ui as in Model 1; l a and l b were considered fixed constants, and we used the same values of l a = l b = 0.1 as previously defined. 12 Model 3: non-hierarchical model with mixture prior on log-odds ratio. We extended a one-stage Bayesian model (Model 1c by Xia et al. 12 ) to Model 3, a non-hierarchical model for the structure of AE data; in this model, no information is borrowed across different AEs within the same body system and all individual AEs are treated independently.
We assumed the same likelihood and mean structure as in Models 1 and 2, but changed the prior distributions at Stage 2 of Model 1 as by Xia et al. 12 
Evaluation of different models and a standard approach
Comparison of measures for the case example. As a measure for safety signal detection, we calculated the following posterior probability to identify potential signals: Pr (OR ij . 1.0 | Data) in an AE of the jth preferred term under the ith system organ class, where OR ij = exp(m uij ) and m uij is the posterior mean of logodds ratios in the Bayesian models for the jth preferred term under the ith system organ class.
Fisher's exact test is a well-established test for investigating associations of AE data with treatment in clinical trials. Therefore, we employed the one-sided p values from Fisher's exact test obtained after simple pooling methods as a standard measure in current practice.
We compared the three models and the standard approach from two points of view: one, comparison of AEs that might exhibit strong associations with treatment; and two, overall comparison of the measures for safety signal detection.
Simulation study
We conducted a simulation study motivated by the data structure of the case example to evaluate the false detection rate and power of our meta-analysis models. We generated 150 patients per group in the first and second trial and 300 patients per group in the third trial. Each trial had 193 preferred terms within 22 system organ classes as in the case example. The incidence probability of an AE in the placebo group was 5%, 10%, 1%, 10%, 5%, and 15% for system organ classes 1, 2, 3-6, 7-11, 12-16, and 17-22, respectively. We assumed that for a true signal the incidence probability in the treatment group was 5% points higher than the corresponding probability in the placebo group. Five preferred terms in the first system organ class and one preferred term in the second system organ class were found to be true signals, and all the other preferred terms were null. The first system organ class and one preferred term in the second system organ class mimicked the system organ class ''Musculoskeletal and connective tissue disorders'' and the preferred term ''dyspepsia,'' respectively, in the case example. We estimated the false detection rate and power for our meta-analysis models using 1000 simulated trials. In this simulation study, the false detection rate was the expected value of the proportion of falsely detected signals among all signals detected. The power was the expected value of the proportion of correctly detected signals among all true signals.
Bayesian computations
We implemented our meta-analysis models within a fully Bayesian framework using Markov chain Monte Carlo methods with WinBUGS software 1.4.3. 26, 27 The sample WinBUGS codes and a detailed method for Bayesian computations are presented in Supplementary appendix. Table 1 presents a top 10 ranking of individual AEs with regard to association with treatment. First, comparison of the results from Model 1 with those from Fisher's exact test after simple pooling revealed that 6/ 10 AEs were identical, and myalgia and dyspepsia were ranked first and second with both methods. The posterior median odds ratios and their 2.5% and 97.5% percentiles from Model 1 were 3.4 (1.1, 12.5) and 3.7 (1.0, 13.8), respectively. In the body system ''Musculoskeletal and connective tissue disorders,'' only myalgia and musculoskeletal pain were detected with Fisher's exact test, whereas myalgia, back pain, musculoskeletal pain, pain in extremity, and periarthritis were detected with Model 1. Second, comparison of the results from Models 1 and 2 revealed that 8/10 AEs were identical, with the top four AEs detected being the same. The posterior median odds ratios and their 2.5% and 97.5% percentiles from Model 2 for myalgia and dyspepsia were 2.4 (1.0, 12.8) and 2.4 (1.0, 14.4), respectively. A notable difference between the two models was observed in the values of the posterior probability; with myalgia, for example, Pr (OR ij . 1.0 Data) = 0.9846 for Model 1, and Pr (OR ij . 1.0 Data) = 0.5942 for Model 2. Thus, the values obtained from Model 2 were considerably smaller than those from Model 1. Third, comparison of the results from Model 3 with those from Fisher's exact test after simple pooling revealed that 6/10 AEs were identical, with the top five AEs detected being the same. However, the estimation of odds ratios from Model 3 was highly unstable: the standard deviations from the posterior samples were extremely large, particularly for AEs for which crude odds ratios cannot be defined (i.e. when the number of patients with AE = 0 in the placebo group). Therefore, Model 3 results are presented for illustration only. Figure 1 shows the relationship between the odds ratios from simple pooling methods and Model 1. The posterior median odds ratios for most of the AEs shrank toward values for no association (i.e. the posterior odds ratios approached 1.0 in the Bayesian model).
Results
A typical example was pharyngitis, for which the crude odds ratio and its 95% confidence interval was 5.0 (0.6, 43.0), whereas the posterior median odds ratio and its 2.5% and 97.5% percentile was 1.3 (0.5, 4.5). This shrinkage was considered reasonable because most of the AEs showed either weak or no association with treatment in our case example. By contrast, the posterior median odds ratio and its 2.5% and 97.5% percentile (2.0 (0.8, 5.7)) were larger than the crude odds ratio and its 95% confidence interval (1.7 (0.6, 4.6)) for back pain, which is differently located above the diagonal line in the figure and is classified under ''Musculoskeletal and connective tissue disorders'' as stated above. Table 2 presents the results of the simulation study by showing the false detection rate and power of Fisher's exact test and our meta-analysis models. Our Model 1 can balance the false detection rate and power to a better extent than Fisher's exact test. For example, when the threshold value of the posterior probability for signal detection was set to 0.8, the false detection rate was 41% and power was 88% from Model 1, whereas the false detection rate was 56% and power was 86% in Fisher's exact test. When we restricted the inference on AEs under the first system organ class, the power was higher compared to the overall result from Model 1. Both false detection rate and power were low from Models 2 and 3 in this scenario, and they were far lower than 20%.
Discussion
We detected more individual AEs under the body system ''Musculoskeletal and connective tissue disorders'' in Model 1 than in Fisher's exact test. To elucidate this result, we examined an extracted tabulation of the incidence of individual AEs under this body system according to treatment group and trial (Table 3) . More incidences were observed in the tadalafil group than in the placebo group for most of the individual AEs. In Model 1, as a property of a Bayesian hierarchical model, strength could be borrowed from both within and across body systems depending on the actual data.
Similar AEs were detected in Models 1 and 2, but a notable difference was observed in their posterior probability values. We consider this difference to be primarily caused by modeling assumptions: in Model 2, we incorporated the belief that a certain proportion of AEs is completely unassociated with treatment by assuming a mixture prior distribution for the mean of log-odds ratios. A similar result was obtained by Berry and Berry 11 and Xia et al., 12 and the posterior probabilities that the odds ratio exactly equals 1.0 were several dozen percent. Based on the simulation results, we recommend using Model 1 in an AE data structure similar to our case example. As indicated in our case example as a property of a Bayesian hierarchical model, Model 1 could suitably detect safety signals under the same system organ class, although the model might detect more non-signals under the system organ class in a compensatory manner. Although Model 2 was not effective in our case example, one potential scenario in which we could use the model is that in which the number of AEs is extremely large, and it would be challenging to handle the large number of safety signals detected in Model 1. The threshold value of the posterior probability for signal detection might depend on the requirement for balancing false-positive and falsenegative rates, but we could use 0.9 as a signal detection rule with Model 1 in an AE data structure similar to our case example, although the power might be slightly low (i.e. 63%).
In our case example, the estimation of odds ratios from Model 3 was highly unstable, but more stable estimates were obtained from Models 1 and 2. Model 3 did not work well also in the simulation study. Certain AEs were still rare at an individual event level for safety meta-analyses, and we expect to frequently encounter a similar type of situation in which the association of individual AEs with treatment is challenging to evaluate. Therefore, employing a Bayesian hierarchical model that considers a hierarchical structure of AEs can also be useful for obtaining stable estimates for an effect measure. For our proposed Bayesian meta-analysis models to be effective, the validity of the hierarchical structure of AEs is also crucial. As discussed by Xia et al., 12 biological relationships among individual AEs are reflected in the medical coding structure, and AEs under the same system organ class are more likely to be similar than other AEs. Thus, they can reasonably borrow strength from each other; this means that ignoring the hierarchical structure will result in a loss of information regarding their relationships. In our case example, the AEs within a top 10 ranking from Model 3 were similar to those from Fisher's exact test, which is also a method that ignores the hierarchical structure. However, one limitation is that the AEs under the same system organ class were not necessarily positively related when we used system organ class and preferred term in Medical Dictionary for Regulatory Activities. For example, the positive relationship was questionable among certain AEs under ''Investigations'': in our case example, both ''white blood cell count increased'' and ''white blood cell count decreased,'' which are clearly counter events, were included under this body system. Therefore, the critical point is the validity of the AE grouping. One possible method to identify events that reflect an identical or highly similar medical concept of interest is to use Standardized MedDRA Queries; medically related AEs that might be under distinct system organ classes are grouped into the same Standardized MedDRA Queries, and AEs can be modeled under the Standardized MedDRA Queries to enable them to borrow strength from each other. 12, 18 Our choice of priors was the same as previously described. 11, 12 Xia et al. 12 conducted some sensitivity analyses for the choice of priors, and they considered their results were robust to different prior distributions. In the case that informative prior distributions are selected, it is necessary to carefully evaluate how the estimates change depending on the selection, although it might be difficult to put some information on specific system organ classes or preferred terms when safety signal detection is performed.
Certain other multivariate meta-analyses for AE data have been proposed, 28, 29 but the approaches adopted were distinct from ours; although AEs were modeled at a comparatively less granular classification of the body system level in one case, 28 AEs were modeled without explicitly considering a hierarchical structure of AEs in another case. 29 All analytic approaches must be selected depending on the objective of the safety meta-analysis and the given AE dataset. Our proposed meta-analysis models are particularly suitable for analyzing entire AE datasets to detect safety signals for further investigation as potential risks from among hundreds or thousands of AEs from multiple randomized clinical trials.
Another limitation of our analysis is that individual patient data from the randomized clinical trials were unavailable, and within-patient dependencies among the individual AEs could not be modeled. When individual patient data are available, such dependencies can be incorporated into Bayesian meta-analysis models, and our models can be extended to Poisson models using an exposure time in person-years in each treatment group.
Recently, there has been considerable interest in comparing multiple treatments, and network metaanalysis is a well-adopted approach for integrating evidence of a complex network of multiple treatments. [30] [31] [32] For safety meta-analyses, a network metaanalytic approach has been proposed for AEs of interest with a pre-specified hypothesis, 33 and general guidance for implementing a safety Bayesian network meta-analysis has been published. 34 Ohlssen et al. 34 discussed a network meta-analysis with a pre-specified event of interest and then extended their model to a multivariate model with borrowing of strength across outcomes. Because their model does not account for a hierarchical structure of AEs, our proposed Bayesian meta-analysis models can be applied to extend their network meta-analytic framework for safety signal detection.
In summary, we have proposed and implemented a new Bayesian meta-analytic approach for individual AE data from multiple randomized clinical trials and for the simulation study motivated by the case example. Our meta-analysis models consider trial effects to avoid confounding by trial and borrow strength from both within and across body systems to obtain reasonable and stable estimates of an effect measure by considering the hierarchical structure of AEs. Different safety signals could be detected among the proposed metaanalysis models and the standard approach depending on the underlying assumptions of each approach. Such differences could lead to distinct interpretations regarding drug safety.
